Published on November 30, 2018. Last updated by CMTA Admin on June 29, 2019.
ALERT! ALERT! ALERT!
Medications added to moderate-to-significant-risk category
Dr. Louis Weimer of Columbia University recently updated the CMTA’s neurotoxic medication list as part of his review for an upcoming issue of Current Neurology and Neuroscience Reports.
There are a number of additions to the moderate-to-high risk category:
- Arsenic Trioxide (Trisenox)
Immune Checkpoint Inhibitors
- Ipilimumab (Yervoy)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
Immunomodulatory Drugs (IMiDs)
- Lenalidomide (Revlimid)
- Pomalidomide (Pomalyst)
Monoclonal Antibodies
- Cetuximab (Erbitux)
- Brentuximab Vedotin (Adcetris)